Intrathecal pain pumps: Indications, patient selection, techniques, and outcomes

Neurosurgery Clinics of North America

Volumn 25, Issue 4, 2014, Pages 735-742

  Bolash, Robert ^a   Mekhail, Nagy ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chronic pain; Intractable spasticity; Intrathecal drug delivery; Intrathecal pain pumps

Indexed keywords

BACLOFEN; BUPIVACAINE; CLONIDINE; FENTANYL; HYDROMORPHONE; MORPHINE; OMEGA CONOTOXIN MVIIA; OPIATE; SUFENTANIL; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT; OMEGA CONOTOXIN;

ANALGESIA; CHRONIC PAIN; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG INDICATION; DRUG RESPONSE; HUMAN; IMPLANTATION; INFUSION PUMP; INTRATHECAL DRUG ADMINISTRATION; INTRATHECAL PUMP; INTRATHECAL TRIALING TECHNIQUE; MEDICAL PROCEDURES; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT SATISFACTION; PATIENT SELECTION; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME; INTRASPINAL DRUG ADMINISTRATION; NEURALGIA; PAIN; PROCEDURES; SPINAL CORD;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; CHRONIC PAIN; HUMANS; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, SPINAL; MORPHINE; NEURALGIA; NOCICEPTIVE PAIN; OMEGA-CONOTOXINS; PAIN; PATIENT SELECTION; SPINAL CORD; TREATMENT OUTCOME;

EID: 84908054471     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2014.06.006     Document Type: Review

References (36)

1. Deer T.R., Prager J., Levy R., et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012, 15(5):436-464.
2. Biggs S.A., Duarte R.V., Raphael J.H., et al. Influence of a latent period in QALY analysis: pilot study of intrathecal drug delivery systems for chronic non-malignant pain. Br J Neurosurg 2011, 25(3):401-406.
3. de Lissovoy G., Brown R.E., Halpern M., et al. Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome. Clin Ther 1997, 19(1):96-112.
4. Deer T.R., Caraway D.L., Kim C.K., et al. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J 2002, 2(4):274-278.
5. Guillemette S., Witzke S., Leier J., et al. Medical cost impact of intrathecal drug delivery for noncancer pain. Pain Med 2013, 14(4):504-515.
6. Kumar K., Hunter G., Demeria D.D. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. JNeurosurg 2002, 97(4):803-810.
7. Mueller-Schwefe G., Hassenbusch S.J., Reig E. Cost effectiveness of intrathecal therapy for pain. Neuromodulation 1999, 2(2):77-87.
8. Roberts L.J., Finch P.M., Goucke C.R., et al. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain 2001, 5(4):353-361.
9. Smith T.J., Staats P.S., Deer T., Implantable Drug Delivery Systems Study Group, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. JClin Oncol 2002, 20(19):4040-4049.
10. Thimineur M.A., Kravitz E., Vodapally M.S. Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. Pain 2004, 109(3):242-249.
11. Winkelmüller M., Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. JNeurosurg 1996, 85(3):458-467.
12. Ver Donck A., Vranken J.H., Puylaert M., et al. Intrathecal drug administration in chronic pain syndromes. Pain Pract 2014, 14(5):461-476.
13. Medtronic (2007, February) retrieved from: medtronic personal therapy manager for synchromed ii physician implant manual. Available at: Accessed July 21, 2014. http://professional.medtronic.com/wcm/groups/mdtcom_sg/@mdt/@neuro/documents/documents/idd-ptm8835-manl.pdf.
14. Dan B., Motta F., Vles J.S., et al. Consensus on the appropriate use of intrathecal baclofen (ITB) therapy in paediatric spasticity. Eur J Paediatr Neurol 2010, 14(1):19-28.
15. McIntyre A., Mays R., Mehta S., et al. Examining the effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: a systematic review. JSpinal Cord Med 2014, 37(1):11-18.
16. Deer T.R., Prager J., Levy R., et al. Polyanalgesic Consensus Conference-2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012, 15(5):420-435.
17. Maier C., Gockel H.H., Gruhn K., et al. Increased risk of suicide under intrathecal ziconotide treatment? - a warning. Pain 2011, 152(1):235-237.
18. Thompson J.C., Dunbar E., Laye R.R. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician 2006, 9(2):147-152.
19. Veizi I.E., Hayek S.M., Narouze S., et al. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med 2011, 12(10):1481-1489.
20. Przybyl J.S., Follett K.A., Caraway D. Intrathecal drug delivery: general considerations. Semin Pain Med 2003, 1(4):228-233.
21. Grider J.S., Harned M.E., Etscheidt M.A. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. Pain Physician 2011, 14(4):343-351.
22. Anderson V.C., Burchiel K.J., Cooke B. Aprospective, randomized trial of intrathecal injection vs. epidural infusion in the selection of patients for continuous intrathecal opioid therapy. Neuromodulation 2003, 6(3):142-152.
23. Kumar K., Kelly M., Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol 2001, 55(2):79-86.
24. Rauck R.L., Cherry D., Boyer M.F., et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. JPain 2003, 4(8):441-447.
25. Pope J.E., Deer T.R. Ziconotide: a clinical update and pharmacologic review. Expert Opin Pharmacother 2013, 14(7):957-966.
26. Wallace M.S., Rauck R.L., Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain 2010, 26(7):635-644.
27. Hayek S.M., Deer T.R., Pope J.E., et al. Intrathecal therapy for cancer and non-cancer pain. Pain Physician 2011, 14(3):219-248.
28. Ellis D.J., Dissanayake S., McGuire D., Elan Study 95-002 Group, et al. Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: a prospective, open-label study. Neuromodulation 2008, 11(1):40-49.
29. Staats P.S., Yearwood T., Charapata S.G., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004, 291(1):63-70.
30. Atli A., Theodore B.R., Turk D.C., et al. Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. Pain Med 2010, 11(7):1010-1016.
31. Belverud S., Mogilner A., Schulder M. Intrathecal pumps. Neurotherapeutics 2008, 5(1):114-122.
32. Saltari M.R., Shaladi A., Piva B., et al. The management of pain from collapse of osteoporotic vertebrae with continuous intrathecal morphine infusion. Neuromodulation 2007, 10(2):167-176.
33. Wallace M.S., Charapata S.G., Fisher R., Ziconotide Nonmalignant Pain Study 96-002 Group, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006, 9(2):75-86.
34. Duse G., Davià G., White P.F. Improvement in psychosocial outcomes in chronic pain patients receiving intrathecal morphine infusions. Anesth Analg 2009, 109(6):1981-1986.
35. Mekhail N., Mahboobi R., Farajzadeh Deroee A., et al. Factors that might impact intrathecal drug delievery (IDD) dose escalation: a longitudinal study. Pain Pract 2014, 14(4):301-308.
36. Bolash RB, Udeh B, Saweris Y, etal. Longevity and Cost of Implantable Intrathecal Drug Delivery Systems for Chronic Pain Management: A Retrospective Analysis of 365 Patients. Neuromodulation "in press".